Literature DB >> 25980999

Practical application of new technologies for melanoma diagnosis: Part II. Molecular approaches.

Jordon March1, Matthew Hand2, Amanda Truong3, Douglas Grossman4.   

Abstract

The criterion standard for diagnosing cutaneous melanoma continues to be histologic examination. However, classifying some melanocytic lesions by conventional microscopy can be problematic if they exhibit some architectural or morphologic characteristics of both nevus and melanoma. Moreover, histologic appearance does not always predict biologic behavior. There is therefore a need and opportunity to develop new technologies that can facilitate the histologic diagnosis of melanoma and potentially help distinguish lesions with a lesser or greater risk of metastasis. In part II of this 2-part continuing medical education article, we will review the molecular technologies currently available for facilitating melanoma diagnosis, including comparative genomic hybridization, fluorescence in situ hybridization, and epidermal genetic retrieval. Our goal is to provide the clinician with an up to date understanding of these molecular approaches so that they can be applied to their management of challenging melanocytic lesions.
Copyright © 2015 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  fluorescence; genomic; hybridization; melanoma; molecular; nevus

Mesh:

Year:  2015        PMID: 25980999     DOI: 10.1016/j.jaad.2015.02.1140

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  9 in total

1.  Identification of melanoma cells: a method based in mean variance of signatures via spectral densities.

Authors:  Esperanza Guerra-Rosas; Josué Álvarez-Borrego; Aracely Angulo-Molina
Journal:  Biomed Opt Express       Date:  2017-03-15       Impact factor: 3.732

2.  Diagnosing Cutaneous leishmaniasis using Fluorescence in Situ Hybridization: the Sri Lankan Perspective.

Authors:  Thilini Dilhara Jayasena Kaluarachchi; Manjula Manoji Weerasekera; Andrew J McBain; Shalindra Ranasinghe; Renu Wickremasinghe; Surangi Yasawardene; Nisal Jayanetti; Rajitha Wickremasinghe
Journal:  Pathog Glob Health       Date:  2019-08-20       Impact factor: 2.894

Review 3.  The changing landscape of dermatology practice: melanoma and pump-probe laser microscopy.

Authors:  Charles J Puza; Paul J Mosca
Journal:  Lasers Med Sci       Date:  2017-09-11       Impact factor: 3.161

Review 4.  Recent advances in molecular genetics of melanoma progression: implications for diagnosis and treatment.

Authors:  Iwei Yeh
Journal:  F1000Res       Date:  2016-06-28

5.  Underexpression of Specific Interferon Genes Is Associated with Poor Prognosis of Melanoma.

Authors:  Aamir Zainulabadeen; Philip Yao; Habil Zare
Journal:  PLoS One       Date:  2017-01-23       Impact factor: 3.240

6.  Construction of hematoxylin-eosin, immunohistochemistry, and EBER-ISH methodology after trichloroisocyanuric acid treatment in melanin-containing tissues.

Authors:  Chaoshan Wang; Xia Yang; Ting Wang; Ya Wang; Jiong Shi; Qi Sun; Yihua Wang; Hongyan Wu
Journal:  Sci Rep       Date:  2022-09-26       Impact factor: 4.996

7.  Diagnosis of melanoma by imaging mass spectrometry: Development and validation of a melanoma prediction model.

Authors:  Rami N Al-Rohil; Jessica L Moore; Nathan Heath Patterson; Sarah Nicholson; Nico Verbeeck; Marc Claesen; Jameelah Z Muhammad; Richard M Caprioli; Jeremy L Norris; Sara Kantrow; Margaret Compton; Jason Robbins; Ahmed K Alomari
Journal:  J Cutan Pathol       Date:  2021-07-02       Impact factor: 1.587

8.  Predictive Nuclear Chromatin Characteristics of Melanoma and Dysplastic Nevi.

Authors:  Matthew G Hanna; Chi Liu; Gustavo K Rohde; Rajendra Singh
Journal:  J Pathol Inform       Date:  2017-04-10

9.  Real-time high-resolution millimeter-wave imaging for in-vivo skin cancer diagnosis.

Authors:  Amir Mirbeik; Robin Ashinoff; Tannya Jong; Allison Aued; Negar Tavassolian
Journal:  Sci Rep       Date:  2022-03-23       Impact factor: 4.996

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.